Acute Coronary Syndrome News and Research RSS Feed - Acute Coronary Syndrome News and Research

ELIXA trial results demonstrate cardiovascular safety of lixisenatide drug

ELIXA trial results demonstrate cardiovascular safety of lixisenatide drug

In patients with type 2 diabetes and acute coronary syndrome, the glucose-lowering medication lixisenatide did not increase or decrease the rate of cardiovascular (CV) events compared to placebo, according to results of the Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) trial. [More]
ESC guideline adherent antithrombotic management improves outcomes in AF patients

ESC guideline adherent antithrombotic management improves outcomes in AF patients

Patients with atrial fibrillation who receive antithrombotic management according to ESC guidelines have better outcomes than those who do not, according to one year follow up results from the ESC's EORP-AF Pilot General Registry presented today at ESC Congress 20151 and published online in Europace. [More]
Vascular side effects prevent first-line ponatinib use in chronic phase CML

Vascular side effects prevent first-line ponatinib use in chronic phase CML

Ponatinib is highly active when given to patients within 6 months of developing chronic phase chronic myeloid leukaemia, phase II results show, but its toxicity profile is unacceptable for first-line treatment. [More]
Cardiome Pharma reports net loss of $7.4 million in second quarter 2015

Cardiome Pharma reports net loss of $7.4 million in second quarter 2015

Cardiome Pharma Corp. today reported financial results for the second quarter and six months ended June 30, 2015. Amounts, unless specified otherwise, are expressed in U.S. dollars and in accordance with generally accepted accounting principles used in the United States of America (U.S. GAAP). [More]
Resverlogix announces formation of international Clinical Steering Committee for RVX-208 "apabetalone" Phase 3 trial

Resverlogix announces formation of international Clinical Steering Committee for RVX-208 "apabetalone" Phase 3 trial

Resverlogix Corp. is pleased to announce the formation of an international Clinical Steering Committee for the RVX-208 "apabetalone" Phase 3 clinical trial BETonMACE assessing major adverse cardiac events (MACE) in high-risk vascular patients with diabetes mellitus and a recent Acute Coronary Syndrome event. BETonMACE is expected to start in the fall of 2015. [More]
Eddingpharm plans to begin Phase 1 study for BRINAVESS in China

Eddingpharm plans to begin Phase 1 study for BRINAVESS in China

Cardiome Pharma Corp. today announced that its Chinese development and commercialization partner, Eddingpharm, plans to initiate a Phase 1 study for BRINAVESSTM to support regulatory approval in China. The study will be conducted in healthy volunteers. [More]
Sanofi announces results from Phase IIIb ELIXA study of Lyxumia in adults with diabetes and high CV risk

Sanofi announces results from Phase IIIb ELIXA study of Lyxumia in adults with diabetes and high CV risk

Sanofi announced today the presentation of full results of the Phase IIIb ELIXA study, which was designed to assess the cardiovascular (CV) safety of Lyxumia (lixisenatide) in adults with type 2 diabetes and high CV risk. [More]
DalCor, MHI partner to conduct Phase III clinical trial of investigational cardiovascular drug

DalCor, MHI partner to conduct Phase III clinical trial of investigational cardiovascular drug

DalCor Pharmaceuticals and the Montreal Heart Institute announced today a collaboration in principle to conduct an international Phase III clinical trial which could result in a major clinical advance in cardiovascular personalised medicine. [More]
Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, today announced the initiation of CALLISTO, a new comprehensive clinical research program for their novel oral anticoagulant, rivaroxaban, in patients with active cancer. The studies are evaluating the medicine for the prevention and treatment of life-threatening blood clots in patients with a wide range of cancer types. [More]
Elderly cardiac patients receive less evidence-based treatment compared to younger patients

Elderly cardiac patients receive less evidence-based treatment compared to younger patients

People in their 80s and 90s are more likely to develop acute coronary syndrome than their younger counterparts. Despite this, they receive less therapy and diagnostic procedures. A doctoral thesis at Sahlgrenska Academy has explored the topic. [More]
Cardiome signs commercialization agreement with AOP for ESMOCARD products

Cardiome signs commercialization agreement with AOP for ESMOCARD products

Cardiome Pharma Corp. today announced that the company has entered a commercialization agreement with AOP Orphan Pharma to sell AOP's cardiovascular products, ESMOCARD and ESMOCARD LYO (esmolol hydrochloride) in Italy, France, Spain and Belgium. [More]
Medicure records net revenue of $3.3 million for first quarter 2015

Medicure records net revenue of $3.3 million for first quarter 2015

Medicure Inc., a specialty pharmaceutical company, today reported its results from operations for the first quarter ended March 31, 2015. [More]
Survey: 52% of acute coronary syndrome patients don't take their prescribed OAP therapy

Survey: 52% of acute coronary syndrome patients don't take their prescribed OAP therapy

People with acute coronary syndrome (ACS) who undergo an angioplasty procedure and receive a heart stent are prescribed an oral antiplatelet (OAP) therapy and aspirin to help prevent a heart attack, a blood clot in their heart stent (stent thrombosis), or even death. [More]
Cardiome Pharma receives reimbursement status for BRINAVESS in Belgium

Cardiome Pharma receives reimbursement status for BRINAVESS in Belgium

Cardiome Pharma Corp. today announced the approval of BRINAVESS for reimbursement by Belgium's national compulsory health care and benefits insurance authority, The National Institute for Health and Disability Insurance (Institut National d'Assurance Maladie Invalidité or INAMI). As a result of this decision, BRINAVESS is expected to be listed for reimbursement in Belgium as of June 1, 2015. [More]
Anticoagulant drug bivalirudin shows mixed results in MATRIX trial

Anticoagulant drug bivalirudin shows mixed results in MATRIX trial

Patients with acute coronary syndrome undergoing angioplasty who received the anticoagulant drug bivalirudin did not show significant improvements in either of two co-primary endpoints--a composite of rate of death, heart attack or stroke at 30 days, or a composite of those events plus major bleeding--as compared to patients receiving standard anticoagulation therapy, according to a study presented at the American College of Cardiology's 64th Annual Scientific Session. [More]
Using arm as access point for catheter-based heart procedures lowers risk of major bleeding, death

Using arm as access point for catheter-based heart procedures lowers risk of major bleeding, death

Patients with acute coronary syndrome undergoing coronary angiogram, a procedure used to assess blockages in the heart's arteries, had a significantly lower risk of major bleeding and death if their interventional cardiologist accessed the heart through an artery in the arm rather than the groin, according to research presented at the American College of Cardiology's 64th Annual Scientific Session. [More]

Cardiac catheterization performed through wrist can reduce bleeding, lower mortality

The groin is the usual access point for investigating or treating the heart with a catheter, but using the wrist as access point reduces bleeding and lowers mortality. These findings are from an international study with major involvement from the University of Bern published today in the Lancet. [More]
New risk-evaluation protocol can help emergency departments evaluate chest-pain patients

New risk-evaluation protocol can help emergency departments evaluate chest-pain patients

A recently developed risk-evaluation protocol can help hospital emergency department personnel more efficiently determine which patients with acute chest pain can be sent home safely, according to a randomized trial conducted at Wake Forest Baptist Medical Center. [More]
Cardiome Pharma records net loss of $18.2 million for 2014

Cardiome Pharma records net loss of $18.2 million for 2014

Cardiome Pharma Corp. today reported financial results for its fourth quarter and year ended December 31, 2014. Amounts, unless specified otherwise, are expressed in U.S. dollars and in accordance with generally accepted accounting principles used in the United States of America (U.S. GAAP). [More]
Survey: Physicians, patients overestimate risk of heart attack or death for possible ACS

Survey: Physicians, patients overestimate risk of heart attack or death for possible ACS

Both physicians and patients overestimate the risk of heart attack or death for possible acute coronary syndrome (ACS) as well as the potential benefit of hospital admission for possible ACS. [More]
Advertisement
Advertisement